Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Anticancer Res. 2012 Aug;32(8):3495-9.
Although combination therapy consisting of 5-fluorouracil (5-FU) and cisplatin for the treatment of gastric cancer has been reported, no consistent regimen has been established. Our aim was to determine the optimal treatment schedule of this therapy, for patients with advanced or recurrent gastric cancer.
We conducted a phase II study to evaluate the efficacy and safety of combination therapy consisting of intermittent 5-FU and low-dose cisplatin in 26 patients with advanced or recurrent gastric cancer. The treatment cycle consisted of intravenous cisplatin at 3.3 mg/m(2)/day for 5 consecutive days. 5-FU was administered as a continuous intravenous infusion at 300-500 mg/body every other day (days 1, 3, 5) for 4 weeks.
The partial response rate was 34.6%. The median survival duration was 12.8 months and the one-year survival was 53.1%. There were a few adverse effects.
Our results suggest that this mode of combination therapy led to a fairly favorable outcome for patients with advanced or recurrent gastric cancer.
虽然已有报道称联合应用氟尿嘧啶（5-FU）和顺铂治疗胃癌，但尚未确立统一的方案。本研究旨在确定晚期或复发性胃癌患者该联合治疗的最佳方案。
我们进行了一项Ⅱ期研究，评估了 26 例晚期或复发性胃癌患者应用间歇 5-FU 和小剂量顺铂联合治疗的疗效和安全性。治疗周期为静脉滴注顺铂 3.3mg/m2/天，连用 5 天。5-FU 为连续静脉滴注，剂量为 300-500mg/体，每 2 天 1 次（第 1、3、5 天），连用 4 周。
部分缓解率为 34.6%。中位生存时间为 12.8 个月，1 年生存率为 53.1%。不良反应较少。
本研究结果表明，该联合治疗方案对晚期或复发性胃癌患者具有较好的疗效。
Zotero 插件